CALC
CalciMedica, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.17
−1.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 7.0K | 46.0K | — | — | — |
| Gross Profit | (7.0K) | (46.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 12.5M | 15.2M | 14.5M | 15.9M | 8.3M |
| SG&A Expense | 7.1M | 7.9M | 9.7M | 22.2M | 5.8M |
| General & Admin Expense | 7.1M | 7.9M | 9.7M | 22.2M | 5.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 19.6M | 23.1M | 24.2M | 38.1M | 14.2M |
| Cost and Expenses | 19.6M | 23.1M | 24.2M | 38.1M | 14.2M |
| Operating Income (EBIT) | (19.6M) | (23.1M) | (24.2M) | (38.1M) | (14.2M) |
| Non-Operating | |||||
| Interest Income | 451.0K | 713.0K | — | — | — |
| Interest Expense | 1.3M | 1.4M | — | 110.0K | 132.0K |
| Net Interest Income | (844.0K) | (709.0K) | — | (110.0K) | (132.0K) |
| Other Non-Op Income/Expense | (1.6M) | (6.4M) | 10.5M | 3.7M | 6.4M |
| Non-Operating Income (excl Interest) | 319.0K | 5.0M | (10.5M) | (3.8M) | (6.5M) |
| EBT (Pre-Tax Income) | (21.2M) | (29.6M) | (13.7M) | (34.4M) | (7.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (21.2M) | (29.6M) | (13.7M) | (34.4M) | (7.8M) |
| Earnings from Cont. Ops | (21.2M) | (29.6M) | (13.7M) | (34.4M) | (7.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (21.2M) | (29.6M) | (13.7M) | (34.4M) | (9.1M) |
| Per Share | |||||
| Basic EPS | ($6.90) | ($9.85) | ($6.10) | ($38.25) | ($116.00) |
| Diluted EPS | ($6.95) | ($9.85) | ($6.10) | ($38.25) | ($116.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 3.4M | 3.0B | 2.2M | 898000 | 306990 |
| Diluted Shares Outstanding | 3.4M | 3.0B | 2.2M | 898000 | 306990 |
| Profitability Metrics | |||||
| EBITDA | (19.9M) | (28.1M) | (13.6M) | (34.2M) | (7.6M) |
| D&A | 31.0K | 46.0K | 58.0K | 58.0K | 52.0K |
| EBIT | (19.9M) | (28.1M) | (13.7M) | (34.2M) | (7.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026